Iptacopan Production Cost Reports

The report provides a detailed analysis essential for establishing an Iptacopan production plant. It encompasses all critical aspects necessary for Iptacopan production, including the cost of Iptacopan production, Iptacopan plant cost, Iptacopan production costs, and the overall Iptacopan production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Iptacopan production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Iptacopan is a medication primarily used to treat complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH). It is primarily used in the treatment of rare kidney diseases, particularly in patients with IgA nephropathy and paroxysmal nocturnal hemoglobinuria (PNH). It works by inhibiting a specific protein in the immune system called complement Factor B, which plays a role in the activation of the complement system.

It helps reduce the damage caused by abnormal immune responses in these conditions. It is mainly used in the treatment of PNH, where it helps to prevent the destruction of red blood cells, thus reducing symptoms like anaemia. In addition, Iptacopan is used to slow down the progression of kidney damage in IgA nephropathy by targeting the immune system’s activity in the kidneys. It is also used in research studies for its potential to treat other rare and complex autoimmune disorders.

The market for Iptacopan is driven by its application as a therapeutic agent in the field of immunology to treat rare kidney diseases, which promotes its demand in the medical sector. Its application as a targeted therapy for diseases, such as paroxysmal nocturnal hemoglobinuria (PNH), also contributes to its demand in the medical and healthcare sectors. Its application as an oral drug for other complement-related conditions, such as kidney diseases like C3 glomerulopathy, further fuels its demand in the medical and pharmaceutical industries.

Industrial Iptacopan procurement mainly depends on factors such as the cost and availability of raw materials, including specialised synthesis compounds, regulatory compliance, and environmental considerations. Innovations in the production process, the reliability of suppliers, sustainability initiatives, and efficient distribution networks all play an important role in shaping the global procurement strategies for Iptacopan.

Raw Material for Iptacopan Production

According to the Iptacopan production plant project report, the major raw materials for Iptacopan production include benzyl 4-oxo-3,4-dihydropyridine-1 (2H)-carboxylate and tert-butyl 4-formyl-5-methoxy-7-methyl-1H-indole-1-carboxylate.

Production Process of Iptacopan

The extensive Iptacopan production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The industrial synthesis of iptacopan starts with the asymmetric addition of 4-(chloromagnesio or bromomagnesio or boronic acid)benzonitrile or benzoic acid derivative to benzyl 4-oxo-3,4-dihydropyridine-1 (2H)-carboxylate by using a metal catalyst and ligand. The reaction leads to the formation of an intermediate. Then, the intermediate formed undergoes enzymatic reduction of the carbonyl, followed by one-pot enzymatic hydrolysis of the cyano to carboxyl, ethylation of the hydroxy, and Pd hydrogenation to remove protection. The intermediate formed is further subjected to reductive amination with another intermediate compound, tert-butyl 4-formyl-5-methoxy-7-methyl-1H-indole-1-carboxylate, under the action of sodium triacetoxyborohydride. Then, the resulting product undergoes hydrolysation and Boc deprotection, followed by HCl salification to give iptacopan hydrochloride as the desired product.

Iptacopan is a Iptacopan is the first oral medication that blocks complement factor B, used to treat paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases. The molecular formula of the compound is C25H30N2O4, and its molecular mass is 422.52 g/mol. It appears as a white solid powder, while the hydrochloride monohydrate salt form exists as a white or almost white to pale purplish-pink powder. The compound has a melting point of 205.5 to 207 degrees Celsius, and its boiling point is around 599.1 degree Celsius. It dissolves in dimethyl sulfoxide but doesn't dissolve well in water, which is common for oral small-molecule drugs. The compound should be stored under dry, dark conditions at 0 to 4 degrees Celsius for short-term storage or at -20 degrees Celsius for long-term storage to maintain stability. It is formulated as 200 mg hard gelatin capsules for therapeutic use to prevent both intravascular and extravascular hemolysis in complement-mediated disorders.